Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
about
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agentPlant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonistsPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateDyspnoea management in acute coronary syndrome patients treated with ticagrelorClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationClopidogrel: the data, the experience, and the controversies.Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administrationSwitching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patientsP2Y12 platelet receptors: importance in percutaneous coronary interventionGuided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Clinical importance of aspirin and clopidogrel resistanceTicagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Tailored antiplatelet therapy and clinical adverse outcomes.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsA comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyPlatelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveAntiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Critical appraisal of ticagrelor in the management of acute coronary syndromeDo Clopidogrel Nonresponders Have an Increased Risk of Adverse Events during Supra-Aortal Angioplasty and Stenting?Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisAcute coronary stent thrombosis in cancer patients: a case series reportNovel antiplatelet agent use for acute coronary syndrome in the emergency department: a reviewAdvances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorSystematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeDesign and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous CoronEfficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome.Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.Acute coronary syndrome in a 100-year-old woman treated successfully with primary percutaneous coronary angioplasty.Ticagrelor for the treatment of arterial thrombosis.Clopidogrel in acute coronary syndrome: implications of recent study findings.Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
P2860
Q24605508-2362F04C-7B5C-4D20-9C3C-7D8B84C072B1Q26829967-F09C869F-B693-4B6F-A530-8771934C9632Q26861282-5C16DAC1-9B0A-45B3-89E8-522468CE5207Q26862694-5EB95B07-281A-47EB-9058-B0AF456BFD6BQ27006031-2B189070-4509-446D-BE05-0C50701ACE8AQ27006816-4DB5C7EF-A5B5-43DE-ACB0-D260CB8B3878Q27011524-FF26383B-54CB-4E80-8C3E-378D299C9A12Q30573045-527A2BF0-BB93-441A-B93C-992124A9B38FQ30827217-19891FF1-8DA3-44DD-90AE-06A5955686CFQ33393300-2EE391E4-C165-4FA6-BF87-D41D109E5279Q33646807-BD3162EF-A36A-45B8-92C4-B9A12224E535Q33655109-EF14625B-7A51-4F64-926E-B45F1BED997AQ33863833-A3F1896E-E7B3-4461-8F9A-2FCAD7A1A1BDQ34014099-B1072909-D986-4FF2-A0B0-1D0E4768C531Q34035039-2AE86EFD-3AD5-4A22-A15A-04DB22110CC7Q34390050-08832100-42D4-42C7-A2C6-779B75B5AD2BQ34404150-52BC00AD-3A4C-4AAA-B2D4-51AC292A9EE8Q34805121-99A99A64-2EDB-41F1-85CB-C91EC9CE18D1Q35032042-641294E9-99F7-4E33-AF60-37E9020D4E9EQ35033722-EE662CA8-AA6D-49AA-8AA9-A49B23E5A88EQ35126038-AFFFFE7F-0D87-41A3-90D7-097730A9C7EBQ35174193-7752B2EF-38D2-40BD-A23B-BC9E2E40916CQ35216396-69F632C9-3ED9-4E14-9936-C80D029038A7Q35373683-8272E943-F9B2-46F8-ADEC-2B3A2C452B54Q35660767-BF8D1AC4-4272-4FDE-9EDA-412C30AB88B1Q35897821-5C20D267-193D-4BD3-96E4-F829A568A434Q36039469-7F741FF6-7630-4580-A622-1AAAED5FFEFAQ36062323-8F4185FA-591A-40EC-9E3D-131C96702FAFQ36131417-B4E0F593-3982-492A-AF98-E1CC18062845Q36676694-B15E5D78-9E98-489D-B34B-292DF949959DQ36807413-8E096F48-7DAD-437B-AD2B-084A2E60C09DQ36841959-B40FAA62-4255-463D-BDBB-E9E2AFF8E303Q36988727-0543BB96-B70B-46CC-98FE-4A6DEF45DB51Q37103506-3EC6B1E4-77FD-4490-A41F-58EF61A6A242Q37509443-B002E292-62CD-47ED-8ED7-E157324BDF0DQ37530040-D57D3E6B-13AC-4BFB-B047-CC806472F8E5Q37561876-75493D39-09E4-46CC-B9D6-34BB65A2F842Q37779806-15EF6D0A-1CAD-4097-BB52-E4A428A67AE8Q37786639-DC44BB46-1376-44F3-8C4E-DE259D5B10F9Q37807874-CE98161A-E23E-482C-A508-BC1D0A896D11
P2860
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@ast
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@en
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@nl
type
label
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@ast
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@en
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@nl
prefLabel
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@ast
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@en
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@nl
P2093
P1433
P1476
Response to ticagrelor in clop ...... therapies: the RESPOND study.
@en
P2093
Cheryl Wei
David Henderson
Dean J Kereiakes
Dharmendra V Patel
Georges Sabe-Affaki
Kathleen Butler
Kevin P Bliden
Lars Rasmussen
Mark J Antonino
Paul A Gurbel
P304
P356
10.1161/CIRCULATIONAHA.109.919456
P407
P577
2010-03-01T00:00:00Z